MX2022004882A - Composicion farmaceutica que comprende selexipag. - Google Patents

Composicion farmaceutica que comprende selexipag.

Info

Publication number
MX2022004882A
MX2022004882A MX2022004882A MX2022004882A MX2022004882A MX 2022004882 A MX2022004882 A MX 2022004882A MX 2022004882 A MX2022004882 A MX 2022004882A MX 2022004882 A MX2022004882 A MX 2022004882A MX 2022004882 A MX2022004882 A MX 2022004882A
Authority
MX
Mexico
Prior art keywords
selexipag
pharmaceutical composition
diphenylpyrazin
butyloxy
isopropylamino
Prior art date
Application number
MX2022004882A
Other languages
English (en)
Inventor
Marc Patrik Schrader
Spain Alexandra Schlicker
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2022004882A publication Critical patent/MX2022004882A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas que comprenden 2-{4-[N-(5,6-difenilpirazin-2-il)-N-i sopropilamino]butiloxi}-N-(metilsulfonil)acetamida (selexipag, NS-304, ACT-293987) que son adecuadas para la administración oral (p.o.).
MX2022004882A 2019-10-23 2020-10-22 Composicion farmaceutica que comprende selexipag. MX2022004882A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019078905 2019-10-23
PCT/EP2020/079698 WO2021078835A1 (en) 2019-10-23 2020-10-22 Pharmaceutical composition comprising selexipag

Publications (1)

Publication Number Publication Date
MX2022004882A true MX2022004882A (es) 2022-08-04

Family

ID=75620412

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004882A MX2022004882A (es) 2019-10-23 2020-10-22 Composicion farmaceutica que comprende selexipag.

Country Status (14)

Country Link
US (1) US20220401441A1 (es)
EP (1) EP4048235A1 (es)
JP (1) JP2022553313A (es)
KR (1) KR20220087443A (es)
CN (1) CN114555088A (es)
AU (1) AU2020369912A1 (es)
BR (1) BR112022007207A2 (es)
CA (1) CA3154802A1 (es)
EC (1) ECSP22040921A (es)
IL (1) IL292354A (es)
JO (1) JOP20220093A1 (es)
MX (1) MX2022004882A (es)
PE (1) PE20221455A1 (es)
WO (1) WO2021078835A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023195957A1 (en) * 2022-04-05 2023-10-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising selexi̇pag processed with wet granulation
WO2023195953A1 (en) * 2022-04-05 2023-10-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising selexi̇pag
WO2023195954A1 (en) * 2022-04-05 2023-10-12 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising a solid dispersion of selexi̇pag
WO2024144679A2 (en) * 2022-12-28 2024-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet formulation comprising selexi̇pag

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
DK2246336T3 (da) 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
WO2009157396A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 脊柱管狭窄症治療剤
CN102065864B (zh) 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
KR102705198B1 (ko) 2009-06-26 2024-09-11 니뽄 신야쿠 가부시키가이샤 결정
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
EP2741738A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Sustained release composition of prostacyclin
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
AU2016366073B2 (en) * 2015-12-02 2021-08-26 Nippon Shinyaku Co., Ltd. Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
US20200397700A1 (en) * 2018-02-21 2020-12-24 Nippon Shinyaku Co., Ltd. Granular composition, production method for granular composition, and dissolution property improvement method for granular composition
JP2022532076A (ja) * 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法

Also Published As

Publication number Publication date
AU2020369912A1 (en) 2022-04-14
JP2022553313A (ja) 2022-12-22
BR112022007207A2 (pt) 2022-07-26
JOP20220093A1 (ar) 2023-01-30
US20220401441A1 (en) 2022-12-22
CN114555088A (zh) 2022-05-27
PE20221455A1 (es) 2022-09-21
CA3154802A1 (en) 2021-04-29
KR20220087443A (ko) 2022-06-24
EP4048235A1 (en) 2022-08-31
ECSP22040921A (es) 2022-06-30
WO2021078835A1 (en) 2021-04-29
IL292354A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
MX2022004882A (es) Composicion farmaceutica que comprende selexipag.
MX2022014458A (es) Derivados de triazina que tienen actividad inhibidora de la replicacion del virus y composicion farmaceutica que constituye el mismo.
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
MX2021004000A (es) Derivados de piperidina.
AR111570A1 (es) Composición farmacéutica que comprende selexipag
CA2725933A1 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
NO20082547L (no) Orale formuleringer omfattende tigecycline
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
WO2017160116A3 (ko) 니코틴아미드 포스포리보실트랜스퍼라제 억제용 신규 화합물 및 이를 포함하는 조성물
EP3384911A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING 2- {4- [N- (5,6-DIPHENYLPYRAZIN-2-YL) -N-ISOPROPYLAMINO] BUTYLOXY} -N- (METHYLSULFONYL) ACETAMIDE
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
MX2021014680A (es) Derivado de benzotriazol.
WO2019194773A3 (en) The combination comprising linagliptin and metformin
MX2020008375A (es) Compuestos de heteroarilo, composiciones farmaceuticas de los mismos y su uso terapeutico.
EA201390603A1 (ru) Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
MX2022007988A (es) Formas cristalinas de (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida.
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
CR20220174A (es) Composición farmacéutica que comprende selexipag
WO2016163818A3 (ko) 2-메톡시-4-(3-(4-메톡시페닐)프로필-1-엔-1-일)페놀을 유효성분으로 함유하는 염증성 질환 또는 관절염 치료 또는 예방용 약학적 조성물
WO2019004980A3 (en) SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE